Wolverine Stack Dosage Guide

Overview

The “Wolverine Stack” pairs Body Protection Compound-157 with Thymosin Beta-4 (TB-500) — two tissue-repair peptides that address complementary stages of the healing cascade. BPC-157 drives local growth factor upregulation and angiogenesis while TB-500 drives systemic actin-mediated cell migration. The result is accelerated recovery from musculoskeletal injuries, tendon/ligament damage, and surgical wounds that neither peptide achieves alone.

This is widely considered the gold-standard healing stack in peptide therapy, with extensive community consensus and growing preclinical evidence.

Mechanism Synergy

BPC-157 and TB-500 converge on tissue repair through distinct and complementary pathways:

BPC-157 (Local Repair Driver)

• Upregulates VEGF (vascular endothelial growth factor) and EGF (epidermal growth factor)
• Activates nitric oxide (NO) signaling for vasodilation and blood flow to injured tissue
• Stimulates fibroblast proliferation and collagen synthesis
• Modulates the FAK-paxillin pathway for cell spreading and migration
• Gastroprotective — heals gut lining, protects against NSAID damage

TB-500 (Systemic Repair Orchestrator)

• Sequesters G-actin monomers, promoting actin polymerization and cytoskeletal reorganization
• Drives cell migration — endothelial cells, keratinocytes, stem cells move toward injury
• Suppresses excessive inflammatory signaling (anti-inflammatory)
• Promotes hair follicle stem cell migration (observed preclinically)
• Upregulates laminin and fibronectin for extracellular matrix remodeling

Combined Healing Cascade:

The net effect: BPC-157 builds the local repair environment while TB-500 recruits the cellular workforce to populate it.

Protocol

Standard Healing Protocol (8–12 weeks)

Loading Phase (Weeks 1-4):

• BPC-157: 500 mcg/day
• TB-500: 5 mg split into 2 doses/week (e.g., Mon/Thu)

Maintenance Phase (Weeks 5-12):

• BPC-157: 250 mcg/day
• TB-500: 2.5 mg once weekly

Timing Notes:

• BPC-157 is timing-flexible — can be injected any time of day
• TB-500 has a long half-life (~hours to days) so timing is not critical
• Never mix in the same syringe/vial — reconstitute and inject separately to preserve stability
• BPC-157 can be injected locally near the injury for targeted effect; TB-500 works systemically regardless of injection site

Cycling:

• Limit continuous use to 90 days maximum
• Follow with 30-day washout to prevent receptor desensitization
• Can repeat cycles as needed for chronic injuries

Acute Injury Protocol (4 weeks)

For acute injuries (sprains, post-surgical), run a compressed high-dose protocol:

• BPC-157: 500 mcg 2x/day (morning + evening)
• TB-500: 5 mg 2x/week
• Duration: 4 weeks, then reassess

Evidence

Preclinical:

• BPC-157 has extensive rodent data showing accelerated healing of tendons, ligaments, muscle, gut mucosa, and bone (Sikiric et al., multiple publications 1993–2024)
• TB-500 (Thymosin Beta-4) preclinical data shows corneal healing, cardiac repair post-MI, and dermal wound closure acceleration
• No published studies on the specific combination, but mechanistic complementarity is well-established

Clinical:

• Neither peptide is FDA-approved for healing indications
• BPC-157 was placed on the FDA’s Category 2 list in 2024 and removed from it in April 2026. Removal is not authorization: BPC-157 is now in no interim category and is not on the 503A bulks list, so there is no lawful compounding route.
• TB-500 followed the same path and remains research-use-only in the US, with no lawful compounding route
• On July 23, 2026 an FDA advisory committee (PCAC) recommended both for the 503A bulks list, against FDA’s own reviewers. The vote is advisory and non-binding; FDA has not adopted it and compounding either is still not permitted.
• Widespread use in integrative medicine, sports medicine, and longevity clinics
• Community consensus strongly supports the combination based on thousands of anecdotal reports

Key Literature:

• Sikiric P. et al., “Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease” (PMC)
• Sosne G. et al., “Thymosin beta 4 promotes corneal wound healing” (PMC)
• Multiple reviews in Pharmaceuticals (2024) on BPC-157 multifunctionality

Considerations

Contraindications:

• Active cancer or tumor history — BPC-157 promotes angiogenesis which could theoretically support tumor vascularization. Avoid in anyone with active malignancy or significant cancer risk
• Pregnancy/breastfeeding — insufficient safety data
• Anticoagulant use — theoretical interaction with BPC-157’s NO modulation; monitor if on blood thinners

Side Effects (Generally Mild):

• Injection site irritation (redness, minor swelling)
• Transient nausea (rare, more common with BPC-157)
• Headache (rare, more associated with TB-500)
• Lethargy during loading phase (TB-500)

Regulatory Status:

• BPC-157: not FDA-approved; removed from Category 2 in April 2026 and now in no interim category; not on the 503A bulks list, so not compoundable
• TB-500: not FDA-approved; same position — no interim category, not on the 503A bulks list, not compoundable
• PCAC recommended both for the 503A bulks list on 2026-07-23; the vote is advisory, FDA has not adopted it, and nothing about their legal status has changed
• Both are banned by WADA and USADA

Stacking Compatibility:

• Pairs well with GHK-Cu for skin/tissue regeneration
• Pairs well with KPV for gut healing (see BPC-157-KPV)
• Compatible with GH secretagogues (CJC-1295/Ipamorelin) for recovery amplification
• No known conflicts with other common peptides at standard doses

See Also

• Related compound: BPC-157
• Related compound: TB-500